^
BIOMARKER:
HRAS G13R
i
Other names: HRAS, HRAS1, Harvey rat sarcoma viral oncogene homolog
Entrez ID:
›
HRAS G13R
|
Urothelial Cancer
|
HRAS G13R
|
Urothelial Cancer
|
tipifarnib Sensitive: C3 – Early Trials
|
tipifarnib Sensitive: C3 – Early Trials
|
HRAS G13R
|
SCCHN
|
HRAS G13R
|
SCCHN
|
tipifarnib Sensitive: D – Preclinical
|
tipifarnib Sensitive: D – Preclinical
|
HRAS G13R
|
Thyroid Gland Carcinoma
|
HRAS G13R
|
Thyroid Gland Carcinoma
|
FRAX597 Sensitive: D – Preclinical
|
FRAX597 Sensitive: D – Preclinical
|
HRAS G13R
|
Thyroid Gland Carcinoma
|
HRAS G13R
|
Thyroid Gland Carcinoma
|
trametinib + dasatinib Sensitive: D – Preclinical
|
trametinib + dasatinib Sensitive: D – Preclinical
|
HRAS G13R
|
Thyroid Gland Carcinoma
|
HRAS G13R
|
Thyroid Gland Carcinoma
|
trametinib Sensitive: D – Preclinical
|
trametinib Sensitive: D – Preclinical
|
HRAS G13R
|
Thyroid Gland Carcinoma
|
HRAS G13R
|
Thyroid Gland Carcinoma
|
dasatinib + SCH772984 Sensitive: D – Preclinical
|
dasatinib + SCH772984 Sensitive: D – Preclinical
|
HRAS G13R
|
Thyroid Gland Carcinoma
|
HRAS G13R
|
Thyroid Gland Carcinoma
|
dasatinib + selumetinib Sensitive: D – Preclinical
|
dasatinib + selumetinib Sensitive: D – Preclinical
|
HRAS G13R
|
Thyroid Gland Carcinoma
|
HRAS G13R
|
Thyroid Gland Carcinoma
|
selumetinib Sensitive: D – Preclinical
|
selumetinib Sensitive: D – Preclinical
|
HRAS G13R
|
Thyroid Gland Anaplastic Carcinoma
|
HRAS G13R
|
Thyroid Gland Anaplastic Carcinoma
|
CI-1040 Sensitive: D – Preclinical
|
CI-1040 Sensitive: D – Preclinical
|
HRAS G13R
|
Solid Tumor
|
HRAS G13R
|
Solid Tumor
|
trametinib Sensitive: D – Preclinical
|
trametinib Sensitive: D – Preclinical
|
